CLINICAL_TRIALS
trial_result
· 2019-02-04
Clinical Trial Update: Dose Evaluation of MK-1966 in Combination With SD-101 in Participants With Advanced Malignancies (MK-1966-001) [Phase 1]
Summary
Phase 1 dose-evaluation of MK-1966 in combination with SD-101 in participants with advanced cancers was terminated. Results have been posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Merck Sharp & Dohme LLC | Conditions: Neoplasms, Advanced | Phase 1 | Status: TERMINATED | Results posted: 2019-02-04